News
1h
Zacks Investment Research on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
2h
Zacks Investment Research on MSNWhy Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-TermTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
Most U.S. drugs rely on ingredients from China, raising safety, quality, and national security concerns. Experts call for ...
The pharmaceutical industry spends a ton of money on drug ads. This should come as no surprise to anyone who watches TV or ...
Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...
MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Opinion: Legal scholar John Shu says a ban or restriction on direct-to-consumer drug advertisements would be illogical and ...
As critics of the pharmaceutical industry have begun floating the idea of banning direct-to-consumer (DTC) pharmaceutical ...
A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results